Vireo Growth (VREOF) Accumulated Expenses (2020 - 2026)
Vireo Growth (VREOF) reported Accumulated Expenses of $33.3 million for Q1 2026, up 667.11% on a YoY basis from $4.3 million in Q1 2025, and up 25.19% sequentially from $26.6 million in Q4 2025.
Vireo Growth (VREOF) Accumulated Expenses (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Accumulated Expenses data on file, last reported at $33.3 million in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses rose 667.11% year-over-year to $33.3 million; the trailing twelve-month figure through Mar 2026 stood at $33.3 million (up 667.11% YoY), and the FY2025 full-year result was $26.6 million, up 288.9% from the prior year.
- Accumulated Expenses climbed to $33.3 million in Q1 2026, from $26.6 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $33.3 million in Q1 2026 to a low of $4.3 million in Q3 2024.
- A 5-year average of $11.4 million and a median of $7.4 million in 2022 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses sank 77.14% in 2024 and soared 667.11% in 2026, its largest moves.
- Tracing VREOF's Accumulated Expenses over 5 years: stood at $6.2 million in 2022, then fell by 21.39% to $4.9 million in 2023, then surged by 40.95% to $6.8 million in 2024, then jumped by 288.9% to $26.6 million in 2025, then advanced by 25.19% to $33.3 million in 2026.
- Business Quant data shows VREOF's Accumulated Expenses at $33.3 million in Q1 2026, $26.6 million in Q4 2025, and $17.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.30 Mn |
| Dec 31, 2025 | 26.60 Mn |
| Sep 30, 2025 | 17.76 Mn |
| Jun 30, 2025 | 17.39 Mn |
| Mar 31, 2025 | 4.34 Mn |
| Dec 31, 2024 | 6.84 Mn |
| Sep 30, 2024 | 4.30 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Mar 31, 2024 | 4.63 Mn |
| Dec 31, 2023 | 4.85 Mn |
| Sep 30, 2023 | 18.80 Mn |
| Jun 30, 2023 | 15.73 Mn |
| Mar 31, 2023 | 5.31 Mn |
| Dec 31, 2022 | 6.17 Mn |
| Sep 30, 2022 | 7.37 Mn |
| Jun 30, 2022 | 7.91 Mn |
| Mar 31, 2022 | 7.62 Mn |
| Dec 31, 2021 | 7.71 Mn |
| Sep 30, 2021 | 3.62 Mn |
| Jun 30, 2021 | 5.61 Mn |